Washington: The swine flu vaccine could become available for use in india this year with an American firm collaborating with an Indian biopharmaceutical company to facilitate the manufacture, clinical development and commercialisation of the vaccine in India. VaxInnate Corporation, based in Cranbury, New Jersey, Tuesday announced that it has granted Indian biopharmaceutical company Biological E. Limited a license to its recombinant H1N1 pandemic swine flu vaccine.
"Biological E. looks forward to working closely with VaxInnate to rapidly develop and manufacture this innovative vaccine in India," said Vijay Kumar Datla, chairman and managing director of BE. "As a leading vaccine provider, we hope to play a key role in protecting Indians and other South Asians from pandemic H1N1 flu." "VaxInnate is pleased to partner with Biological E. to meet the H1N1 vaccine needs of India and to demonstrate the speed and volume capabilities of our proprietary vaccine technology," said Alan Shaw, president and CEO of VaxInnate. "We will continue to pursue domestic and other international partnerships for development of this and other vaccines to meet global needs." VaxInnate`s proprietary technology - based upon a combination of toll-like receptor-mediated (TLR) immune enhancement and recombinant bacterial production of vaccine antigen - conveys significant speed and volume advantages, making it capable of producing hundreds of millions of vaccine doses in weeks instead of months. Meanwhile, VaxInnate plans to pursue clinical development and licensure of pandemic and seasonal flu vaccines in the US. -IANS
Zee-Taleem Poll Survey on Elections 2014
Under gunpoint, I will choose Modi as PM: Kejriwal
Delhi gang-rape: Death upheld for 4 convicts
Is there a surge of support for Narendra Modi?